Reimbursement:
GAO TARGETS NEW AWP PAYMENT HEMORRHAGE
Published on Wed Nov 06, 2013
As with most covered drugs and biologicals,Medicare pays way too much for blood clotting factor, the General Accounting Office maintains in a report released Feb. 12. The culprit is familiar: Payment for blood clotting factor — a biological used by hemophiliacs to prevent uncontrolled internal bleeding — is based on the now-notorious “average wholesale price,” a manufacturer-set price some critics [...]